0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Plasma Alpha-Subunit Levels during the Treatment of Pituitary Adenomas with the Somatostatin Analog (SMS 201-995)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effect os SMS 201-995 (Sandostatin), a long-acting somatostatin analog, on different types of pituitary adenomas including α-subunit elevation is illustrated in this report. Treatment induced a fall in hCG levels in a woman with a pituitary adenoma producing only α-subunit. In 3 acromegalic patients, there was only a partial drop in GH and α-hCG. The same effect was observed in a woman with menopausal FSH and LH levels. SMS reduced plasma TSH and α-hCG in a case of thyrotropic adenoma. Two patients exhibiting FSH- and α-hCG-secreting adenomas did not respond to acute administration of SMS 201–995. More patients have to be treated before a definitive statement can be made on the usefulness of somatostatin analogs in the management of different types of pituitary adenomas.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-4809-0
          978-3-318-01960-5
          1663-2818
          1663-2826
          1988
          1988
          28 November 2008
          : 29
          : 2-3
          : 124-128
          Affiliations
          Centre de Médecine Nucléaire, Service de Radiopharmacie et Radioanalyse, Hôpital Neuro-Cardiologique, Lyon, France
          Article
          180987 Horm Res 1988;29:124–128
          10.1159/000180987
          2456975
          © 1988 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Somatostatin: Recent Advances in Basic Research and Clinical Applications

          Comments

          Comment on this article